Full Press Release Details
SAN DIEGO, Sept. 10, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Yuichi Iwaki, M.D., PhD., Chief Executive Officer of MediciNova, will present a company overview at the 2007 UBS Global Life Sciences Conference on Wednesday, September 26, 2007 at 2:00 p.m. Eastern time. The conference is being held at the Grand Hyatt Hotel in New York City.
A live webcast of the presentation can be accessed through the Investor Relations webpage of MediciNova's website at http://investors.medicinova.com . An archived version of the presentation will be available for approximately 60 days following the event.
MediciNova, Inc. is a publicly-traded biopharmaceutical company that acquires well characterized small-molecule drugs through strategic alliances with Japanese and other international pharmaceutical companies and accelerates their development in a diversified portfolio of therapeutic product candidates targeting significant disease markets. MediciNova's pipeline, which includes six compounds in clinical testing, targets a variety of prevalent medical conditions, including asthma, multiple sclerosis, status asthmaticus, interstitial cystitis, cancer, Generalized Anxiety Disorder, insomnia, preterm labor, urinary incontinence and thrombotic disorders. MediciNova's strategy is to commercialize selected product candidates in the United States and to monetize other programs at key value inflection points. For more information on MediciNova, Inc., please visit www.medicinova.com
The MediciNova, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3135